miv-cel (mivocabtagene autoleucel) — Full data
2026
Lupus Nephritis: Report Phase 1 data in 2026Source filing
KYTX biotech catalysts & pipeline
KYVERNA THERAPEUTICS INC · Data as of 2026-10-25
Upcoming catalysts
miv-cel (mivocabtagene autoleucel) — Initial data
Q4 2026
Kyverna expects to provide an update on its PMS development strategy by early 2027, as well as additional data from the Stanford Phase 1 IIT in Q4 2026.Source filing
miv-cel (mivocabtagene autoleucel) — Rolling NDA/BLA submission
Q4 2026
Sustained clinical benefit and reversal of disability through one year support the potential to be the first approved therapy in SPS and first approved CAR T-cell therapy for autoimmune disease; rolling BLA submission on track for completion in Q4 2026Source filing